HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
SAN DIEGO, Jan. 11, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it has elected to…
47,160$
0,49%
Echtzeit-Aktienkurs Halozyme Therapeutics
Bid:
Ask:
Nachrichten zur Halozyme Therapeutics Aktie
Halozyme Therapeutics Stock Down 8% on 2022, 2023 Revenue Guidance
Halozyme Therapeutics Stock Down 8% on 2022, 2023 Revenue Guidance...…
Halozyme issues 2023 revenue, adj. EPS guidance below estimates, shares fall ~7%
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Halo Therapeutics stock drops following weak 2023 outlook
Halozyme Therapeutics Inc. HALO stock fell in the extended session Tuesday after the biotech drug maker’s 2023 forecast disappointed Wall…
Halozyme Provides 2023 Financial Guidance and Outlook
2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from…
Form 8-K HALOZYME THERAPEUTICS, For: Jan 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…